cab-axl-adc
cab-axl-adc: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: BioAtla, Inc. (BCAB)
Development Pipeline (1)
| Company | Phase |
|---|---|
| BioAtla, Inc. (BCAB) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Frequently asked questions
Who is developing cab-axl-adc?
cab-axl-adc is being developed by BioAtla, Inc..
How many clinical trials involve cab-axl-adc?
BioSniper tracks 1 clinical trial involving cab-axl-adc.
Analyze BioAtla, Inc. & cab-axl-adc with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company